Mylan Canada Receives Health Canada Approval for Generic Version of Tracleer®
PITTSBURGH and TORONTO, June 6, 2012 /CNW/ - Mylan Inc. (Nasdaq: MYL) today announced that its Canadian subsidiary, Mylan Pharmaceuticals ULC, has received approval from Health Canada for Mylan-Bosentan Tablets, 62.5 mg and 125 mg. Mylan-Bosentan is the generic version of Actelion Pharmaceuticals Ltd.'s Tracleer®, used for the treatment of pulmonary arterial hypertension(1). According to IMS Health, Bosentan Tablets had Canadian sales of approximately $37.8 million(2) for the 12 months ending March 31, 2012.
"Providing Canadians access to high quality, affordable medicines is our primary goal," said Dick Guest, Mylan Canada's President and CEO. "By providing access to more affordable generic drugs, Mylan helps to reduce the burden on our health care system, benefiting all Canadians."
Currently, Mylan Canada has 38 product applications pending Health Canada approval. These 38 products represent $2.6 billion in annual sales for the 12 months ending March 31, 2012, according to IMS Health.
In Canada, generic drugs cost consumers an average of 60% less than their brand name counterparts.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com For more information about Mylan in Canada, please visit www.mylan.ca. For more information about generic drugs, please visit www.ChoosingGenerics.ca.
(1) Bosentan should not be taken by people who are allergic or women who are pregnant or could become pregnant, as it may cause birth defects. Bosentan has also been reported to affect the liver, including rare reports of hepatic cirrhosis and liver failure, and requires periodic monitoring of liver enzymes. Caution should be used in patients with liver disease, chronic heart failure and low blood pressure.
(2) All sales figures are in Canadian dollars.
SOURCE Mylan Inc.For further information:
Nina Devlin (Media), +1-724-514-1968, or Kris King (Investors), +1-724-514-1813; or Jeff Mehltretter, (Mylan Pharmaceuticals ULC), +1-416-236-2631 x21221